Regular
NAV (05-Sep-24)
Returns (Since Inception)
Fund Size
₹3,203 Cr
Expense Ratio
1.98%
ISIN
INF200K01446
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
31 Dec 2004
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+48.26%
+54.79% (Cat Avg.)
3 Years
+20.60%
+18.09% (Cat Avg.)
5 Years
+29.99%
+29.12% (Cat Avg.)
10 Years
+14.38%
+15.75% (Cat Avg.)
Since Inception
+16.05%
— (Cat Avg.)
Equity | ₹3,082.26 Cr | 96.24% |
Others | ₹120.4 Cr | 3.76% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹382.55 Cr | 11.94% |
Divi's Laboratories Ltd | Equity | ₹183.38 Cr | 5.73% |
Lupin Ltd | Equity | ₹179.22 Cr | 5.60% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹174.37 Cr | 5.44% |
Cipla Ltd | Equity | ₹165.49 Cr | 5.17% |
Lonza Group Ltd ADR | Equity | ₹164.45 Cr | 5.13% |
Poly Medicure Ltd | Equity | ₹149.25 Cr | 4.66% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹126.55 Cr | 3.95% |
Aether Industries Ltd | Equity | ₹124.64 Cr | 3.89% |
Jupiter Life Line Hospitals Ltd | Equity | ₹120.41 Cr | 3.76% |
Aurobindo Pharma Ltd | Equity | ₹113 Cr | 3.53% |
Mankind Pharma Ltd | Equity | ₹111.95 Cr | 3.50% |
Abbott India Ltd | Equity | ₹105.69 Cr | 3.30% |
Treps | Cash - Repurchase Agreement | ₹104.84 Cr | 3.27% |
Torrent Pharmaceuticals Ltd | Equity | ₹104.55 Cr | 3.26% |
Alkem Laboratories Ltd | Equity | ₹92.56 Cr | 2.89% |
Gland Pharma Ltd | Equity | ₹91.93 Cr | 2.87% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹82.71 Cr | 2.58% |
Rainbow Childrens Medicare Ltd | Equity | ₹76.05 Cr | 2.37% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹73.21 Cr | 2.29% |
Ami Organics Ltd | Equity | ₹72.39 Cr | 2.26% |
Fortis Healthcare Ltd | Equity | ₹66.22 Cr | 2.07% |
Suven Pharmaceuticals Ltd | Equity | ₹64.41 Cr | 2.01% |
Dr. Lal PathLabs Ltd | Equity | ₹61.02 Cr | 1.91% |
Laurus Labs Ltd | Equity | ₹56.42 Cr | 1.76% |
Vijaya Diagnostic Centre Ltd | Equity | ₹54.76 Cr | 1.71% |
Gufic Biosciences Ltd | Equity | ₹40.24 Cr | 1.26% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹40.21 Cr | 1.26% |
Net Receivable / Payable | Cash - Collateral | ₹15.56 Cr | 0.49% |
Emcure Pharmaceuticals Ltd | Equity | ₹4.23 Cr | 0.13% |
Sanofi Consumer He | Equity | ₹0.44 Cr | 0.01% |
Large Cap Stocks
31.09%
Mid Cap Stocks
29.21%
Small Cap Stocks
29.04%
A
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,884.79 Cr | 90.07% |
Basic Materials | ₹197.03 Cr | 6.15% |
Standard Deviation
This fund
14.84%
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
0.95
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Since June 2011
Since December 2023
ISIN | INF200K01446 | Expense Ratio | 1.98% | Exit Load | No Charges | Fund Size | ₹3,203 Cr | Age | 31 Dec 2004 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹14.97 Cr | 55.2% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹791.70 Cr | 56.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹791.70 Cr | 54.1% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹31.78 Cr | 52.5% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹183.39 Cr | 55.6% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹183.39 Cr | 52.7% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2560.38 Cr | 53.4% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2560.38 Cr | 51.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 52.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.87 Cr | 51.4% |
Total AUM
₹10,76,433 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Your principal amount will be at Very High Risk